Early Detection · Clinical Intelligence · Kidney Disease

Detect kidney injury earlier. Give clinicians the intelligence to act.

Renalis Glofil Health develops AI-powered clinical decision support that identifies emerging kidney injury, explains patient risk to the responsible clinician, and delivers actionable intelligence in time to change the outcome — in resource-limited hospitals and NHS Trusts alike.

See the Platform Request a Clinical Demonstration

13M+

Kidney disease cases requiring clinical intervention each year

1.7M

Deaths each year from kidney disease — a significant proportion occurring in settings where earlier clinical intelligence could have changed the outcome

3 Markets

Nigeria, United Kingdom, United States — one integrated platform

End-to-End

Intelligence across the full care continuum, from community to intensive care

About

The clinical intelligence that kidney disease outcomes depend on

Renalis Glofil Health is a Liverpool-based medical technology company with a single founding purpose: to ensure that no patient suffers an avoidable outcome from kidney disease through failure of timely clinical intelligence.

Kidney disease, across its full spectrum from early chronic kidney disease through to acute presentations, carries one of the most preventable mortality burdens in medicine. The evidence exists. The clinical frameworks exist. What is absent, in too many hospitals and too many clinical settings, is the infrastructure to translate laboratory data into clinical action at the moment it is needed. That is the problem Renalis was founded to solve.

Our platform addresses the complete clinical pathway: detecting early indicators of kidney disease in at-risk populations, supporting clinical decision-making in acute presentations, and providing continuous monitoring for patients whose condition demands it. The products of the Renalis Suite are not parallel offerings. They form a single, integrated intelligence system that follows the patient across the entire care continuum.

"In too many hospitals — on both sides of the Atlantic and across sub-Saharan Africa — patients deteriorate from an entirely treatable condition because the right information did not reach the right clinician in time. We were founded to change that." Moses Omughele, Founder and Chief Executive Officer

We build for the settings where the burden is greatest. Sub-Saharan Africa carries a disproportionate share of the global kidney disease burden, driven by population genetics, infectious disease exposure, environmental factors, and a scarcity of diagnostic and decision-support infrastructure. Building for those conditions first does not constrain the platform. It makes it genuinely dependable across every environment that follows.

United Kingdom Entity

Renalis Glofil Health Ltd
Companies House No. 17147097
Liverpool, Merseyside

Nigerian Entity

Renalis Glofil Health Nigeria Limited
Corporate Affairs Commission No. 9508519

Regulatory Pathway

Products are in development stage. Target regulatory submissions: NAFDAC in Nigeria, MHRA Class IIa in the United Kingdom, and FDA in the United States. No regulatory authorisation is currently held or implied.

Clinical Sites

Active clinical research partnerships are in place at Delta State University Teaching Hospital, Oghara, and Federal Medical Centre Ovwian, both in Delta State, Nigeria. Research collaboration agreements are signed and in force.

The Scientific Foundation

Built on population science, not population assumptions

The clinical AI problem in kidney disease is not computational. It is epistemic. Most existing tools were trained on data that does not reflect the populations most affected. We are building differently.

Genetic Architecture

APOL1 risk variants and their interaction with infectious, inflammatory, and environmental exposures are central to the kidney disease burden in West African populations. Our platform is designed to incorporate genetic risk intelligence into clinical decision support.

Population-Specific Reference Data

Clinical reference intervals derived from populations with different genetic backgrounds and disease exposures differ materially from those underpinning existing tools. Our validation programme generates reference data from the populations we serve.

Inflammatory and Environmental Pathways

Interferon signalling, complement activation, and environmental exposures interact with genetic risk in ways that existing clinical tools do not capture. Our models are designed to accommodate this complexity from the outset.

Longitudinal Intelligence

Epigenetic ageing markers, mitochondrial indicators, and longitudinal biomarker trajectories provide clinical intelligence that single-timepoint measurements cannot. Our platform reasons across time, not just across individual results.

Clinical Principles

The standards that govern everything we build

These are not values statements. They are engineering requirements: the conditions that every product decision must satisfy before it proceeds.

Early Recognition

The earliest possible identification of kidney disease, before clinical deterioration becomes irreversible. Time is the critical variable in kidney health outcomes.

Clinician-Centred Guidance

Evidence-based, context-aware guidance delivered to the right clinician at the right moment, calibrated for the setting in which they practise and not a generic clinical environment.

Transparent Reasoning

Every recommendation is accompanied by the evidence that underpins it. Clinicians understand the reasoning and are never asked to accept a conclusion without a basis.

Designed for Real Conditions

Built for environments with intermittent connectivity, constrained laboratory infrastructure, and diverse clinical aetiologies. Not idealised conditions that do not exist in practice.

The Renalis Suite

One platform. Every setting.

Five distinct products spanning the full care continuum, from community-level alerting to continuous intensive care monitoring. They share a single intelligence architecture, so that clinical insight reaches the right clinician at the right moment, wherever they are.

Clinical Alerting · Community and Ward

SMS Alert System

An intelligent alerting system that connects directly to hospital laboratory infrastructure, analyses results in real time, and delivers targeted clinical notifications to ward staff on any mobile device, over any network. No smartphone required. Designed for environments where consistent connectivity cannot be assumed.

Active Development

Clinical Decision Support · Mobile

Mobile Clinical Application

A mobile application for ward clinicians presenting patient risk information in a clear, priority-ranked interface. Fully functional without an internet connection. Designed for the hardware and network conditions of real clinical environments, not demonstration settings.

Active Development

Clinical Decision Support · Hospital

Hospital Clinical Decision Support

A comprehensive clinical decision support system for hospital environments. Integrates with existing laboratory and patient record infrastructure to provide real-time clinical intelligence across the hospital, with full audit and governance capability built in from the ground up.

Active Development

Clinical Decision Support · NHS and International

NHS and International Clinical System

A clinical decision support system built for NHS Trust environments and international hospital systems, integrated directly into existing electronic patient record workflows. Clinicians receive guidance without leaving their clinical system. Designed from the outset to meet MHRA, NHS, and international regulatory requirements.

In Development

Continuous Monitoring · Wearable Device

Continuous Patient Monitor

A wearable device that tracks key physiological parameters in real time, providing clinical intelligence between scheduled laboratory measurements and so that deterioration is detected at the earliest possible moment. Designed for intensive care environments in both Nigerian hospitals and NHS Trusts, with a target of 48-hour battery life and wireless connectivity to the clinical platform.

Hardware Prototype · In Development

How the Platform Works

Five products. One intelligence system.

The Renalis Suite is not a collection of separate tools. Each product feeds into and draws from a shared clinical intelligence architecture, so that a result captured in the community informs the ward decision, and the ward decision informs the specialist review.

Data Capture

Laboratory results, vital signs, and clinical observations enter the platform from hospital systems, ward devices, and the wearable monitor.

Analysis

The AI engine analyses incoming data against validated clinical reference intervals, risk models, and longitudinal patient trajectories.

Alert and Guidance

Actionable intelligence is delivered to the appropriate clinician via SMS, mobile application, or integrated clinical system, with the reasoning made explicit.

Clinical Decision

The clinician reviews the guidance, interrogates the evidence, and acts. Every output is a support tool. The clinician remains in command.

Continuous Learning

Outcomes and clinical decisions are captured under governance to refine and validate the platform's performance over time.

Our Approach

Built for the hardest settings first

Most medical technology is designed for well-resourced environments and adapted imperfectly for others. We have inverted that model. Building for the most constrained clinical realities first produces a platform that performs with equal precision in every environment that follows.

Context-Aware Intelligence

Our AI models are trained and validated on clinical data that reflects the disease patterns, patient demographics, and resource constraints of the environments in which they operate, not transplanted from settings with entirely different clinical profiles.

Infrastructure-Independent Design

The platform functions with intermittent connectivity, limited laboratory infrastructure, and basic mobile devices. Resilience is an architectural requirement. The system maintains clinical utility even when the environment falls short of ideal.

Regulatory Rigour from Day One

Every design decision is made with the end regulatory submission in mind: NAFDAC in Nigeria, MHRA in the United Kingdom, and FDA in the United States. Compliance is built in, not bolted on.

Clinical Partnership at the Centre

Every product decision is made in active collaboration with practising clinicians at our partner institutions. Clinical credibility is not a marketing asset. It is the scientific foundation on which the platform is built.

Data Sovereignty

Patient data collected in Nigeria is governed under Nigerian law and stored on Nigerian infrastructure. Patient data collected in the United Kingdom is governed under UK GDPR. No cross-border transfer occurs without the legal frameworks required by each jurisdiction.

Permanence, Not Pilots

Our pricing model is designed to remain affordable in every market we serve, permanently and not only during the launch phase. Commercial viability and clinical access are not in conflict. We have built the business to demonstrate that they are not.

"The greatest clinical risk in any AI health system is not that the algorithm is wrong. It is that the clinician cannot interrogate why. We will never deploy a system whose reasoning cannot be examined." Moses Omughele, Founder and Chief Executive Officer

Development Programme

Three phases. One trajectory.

A disciplined, evidence-led programme from clinical validation through to multi-market deployment and international regulatory approval.

Years 1 to 3 — Current

Feasibility and Validation

Anchor clinical partnerships established, with host institution agreements signed and in force
Prospective clinical studies designed and submitted for regulatory review
Nigerian regulatory pre-submission dossier in preparation
Competitive grant applications submitted to UK and international health programmes
Wearable monitor hardware prototypes under development
UK scientific advisory board in formation
Seed investment round in progress

Years 4 to 6

Scale and Regulatory Approval

Nigerian regulatory approval and commercial launch
MHRA Class IIa registration and UK market entry
NHS digital health assessment certification
Series A investment round completed
US regulatory pre-submission programme initiated
Multi-hospital commercial deployment in Nigeria
Executive leadership team fully appointed

Years 7 to 10

Global Platform

US regulatory clearance and American market entry
Series B investment round completed
Pan-African expansion across West, East, and Southern Africa
NHS national procurement framework listing
Next-generation diagnostic device programme commenced

Mission and Vision

Eliminate preventable kidney disease mortality through AI, across Nigeria, the NHS, and globally.

Our vision is simple and absolute: a world in which no patient dies from kidney disease that could have been detected and acted upon in time. Not in London. Not in Lagos. Not anywhere that Renalis Glofil Health has the privilege of operating.

That is not a corporate aspiration. It is the clinical standard against which every decision this company makes — every design choice, every partnership, every regulatory submission — is measured.

"No patient in any hospital where Renalis Glofil Health operates should die from kidney disease that our technology could have detected in time. That is not a mission statement. That is a clinical standard." Moses Omughele, Founder and Chief Executive Officer

"We chose to build for the most under-resourced hospitals first, not because it was the easiest path to market, but because that is where the unmet need is greatest and where our work will matter most."

Our Commitments

What we hold ourselves to

These are not aspirational. They are the conditions of operation that govern every product we release and every partnership we form.

Scientific Rigour

No product will be released without independent clinical validation. All outcomes are measured against peer-reviewed benchmarks. We will publish our validation data in full and will not make efficacy claims that we cannot defend in a peer-reviewed journal.

Clinical Safety First

Every recommendation the system produces is a decision-support output, never a replacement for clinical judgement. The clinician remains in command, with the ability to interrogate, modify, and override every output the platform produces.

Explainability as Standard

We do not deploy opaque systems in clinical environments. Every recommendation is accompanied by the evidence and reasoning that underpins it. Explainability is a design requirement, not a feature added after the fact.

Data Sovereignty

Patient data is governed under the laws of the jurisdiction in which it is collected. Data collected in Nigeria stays in Nigeria. Data collected in the United Kingdom stays in the United Kingdom. Jurisdictional boundaries are respected absolutely.

Equity by Design

We build first for the settings most underserved by conventional medical technology. High-income market products are extensions of that foundation, not the origin of it.

Long-Term Sustainability

Our pricing model is built to remain affordable in every market we serve, permanently. Commercial success and clinical access are not in conflict. We have designed the business to prove that they are not.

Clinical Partnerships

Built with the institutions that face this challenge every day

Every product decision is grounded in active clinical partnership with practising clinicians and hospital teams. Partnership is not a marketing activity. It is the scientific foundation of everything we build.

Nigeria · Active Research Partnerships

Teaching and Specialist Hospital Partnerships

Clinical research partnerships are active at Delta State University Teaching Hospital, Oghara and Federal Medical Centre Ovwian, both in Delta State, Nigeria. Formal agreements are in force at both sites. Clinical validation activities are under way, generating the population-specific data that underpins the platform's AI models.

United Kingdom · Scientific Advisory Board

UK Nephrologist Advisory Panel

A UK nephrologist advisory panel is being established, spanning AKI clinical guideline leadership, NHS critical care nephrology, clinical AI deployment, and national renal policy. The panel will provide independent clinical oversight of all product development and validation activities.

Funding and Growth

Investment and Grant Pipeline

We are in active discussions with UK health-focused pre-seed investors and have submitted applications to multiple competitive grant programmes. Our funding strategy is deliberately non-dilutive in the early phase, preserving equity for the clinical milestones that drive valuation most significantly.

Team

Leadership

Moses Omughele

Founder and Chief Executive Officer

MSc Data ScienceUniversity of East London, 2026
MPH International Public HealthLiverpool John Moores University
MBA Business AdministrationWrexham University (ongoing)
PGCert Human AnatomyUniversity of Glasgow
BSc Human AnatomyUniversity of Maiduguri
GCP Good Clinical Practice (ICH E6 R3)NIHR / UK Research Integrity, 2026

Moses Omughele is the founder and architect of Renalis Glofil Health Ltd. His academic background spans human anatomy, international public health, data science, and business: a combination both unusual and directly relevant to the challenge of building clinical AI for global health settings.

He combines the clinical understanding to define what the system must do, the technical capability to build it, and the public health perspective to ensure it reaches the populations that need it most. His training spans the histological architecture of the kidney, population-level epidemiological modelling, and data science — a range that is unusual and directly relevant to the challenge of building clinical AI for resource-variable health settings.

"We are not building a product for clinicians to trust. We are building a product that earns trust — through clinical evidence, regulatory rigour, and transparent reasoning, every step of which will be published for scrutiny." Moses Omughele, Founder and Chief Executive Officer

Renalis Glofil Health Ltd is registered in England and Wales (Companies House No. 17147097) and is headquartered in Liverpool, Merseyside. The company operates through its Nigerian entity, Renalis Glofil Health Nigeria Limited (CAC No. 9508519).

"The academic institutions that trained me — from Maiduguri to Glasgow to Liverpool — gave me a perspective that no single discipline could have. This company is the convergence of all of them." Moses Omughele, Founder and Chief Executive Officer

Get in Touch

Request a demonstration or discuss a partnership

We welcome enquiries from clinical institutions, NHS Trusts, investors, regulatory bodies, and global health partners. All demonstrations are tailored to your specific context and conducted by appointment.

Emailinfo@renalisglofilhealth.com
ResponseWithin 2 business days
LocationLiverpool, Merseyside, England
LinkedInlinkedin.com/in/moses-omughele
DemosBy appointment only, confidential

I am a

Full Name

Job Title

Organisation

Country

Email Address

Phone

Your Message

Preferred contact method

Your information is handled in accordance with UK GDPR. It will be used solely to respond to your enquiry and will not be shared with third parties.